News | September 23, 2023
Lupin acquires five brands from Menarini
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Lupin has been exclusively marketing these brands in the Indian market since July 2021
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
The hospital hosted a two-day event with top internal and external faculty and medical experts
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Oteseconazole Capsules were found to be safe and more effective than fluconazole
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Subscribe To Our Newsletter & Stay Updated
